Compare BIO & SEIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BIO | SEIC |
|---|---|---|
| Founded | 1952 | 1968 |
| Country | United States | United States |
| Employees | 7450 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Investment Bankers/Brokers/Service |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 9.8B |
| IPO Year | N/A | 1995 |
| Metric | BIO | SEIC |
|---|---|---|
| Price | $281.97 | $77.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $339.75 | $103.29 |
| AVG Volume (30 Days) | 269.3K | ★ 688.7K |
| Earning Date | 04-30-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.38% |
| EPS Growth | N/A | ★ 27.66 |
| EPS | N/A | ★ 5.63 |
| Revenue | N/A | ★ $2,297,381,000.00 |
| Revenue This Year | $2.59 | $16.09 |
| Revenue Next Year | $3.21 | $7.31 |
| P/E Ratio | ★ $9.72 | $13.35 |
| Revenue Growth | N/A | ★ 8.10 |
| 52 Week Low | $211.43 | $69.04 |
| 52 Week High | $343.12 | $93.96 |
| Indicator | BIO | SEIC |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 47.07 |
| Support Level | $256.85 | $75.69 |
| Resistance Level | $289.61 | $84.05 |
| Average True Range (ATR) | 7.95 | 1.62 |
| MACD | 2.05 | 0.05 |
| Stochastic Oscillator | 75.33 | 55.32 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
SEI Investments provides investment processing, management, and operations services to financial institutions, asset managers, asset owners, and financial advisors in four material segments: private banks, investment advisors, institutional investors, and investment managers. SEI also has a minority interest in LSV Asset Management, a value equity asset manager with about $99 billion in assets under management. As of December 2025, SEI (including LSV) manages, administers, or advises about $1.9 trillion in assets.